Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 677-680

  Andrews, Jenny ^a   Honeybourne, D ^b   Ashby, J ^a   Jevons, G ^a   Fraise, A ^a   Fry, P ^c   Warrington, S ^c   Hawser, S ^d   Wise, R ^a  

^a CITY HOSPITAL   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^d Arpida Ltd   (Switzerland)

Author keywords

Concentration; Diaminopyrimidine; Respiratory tree

Indexed keywords

ICLAPRIM; PENICILLIN G;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BRONCHUS MUCOSA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN EXPERIMENT; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; NORMAL HUMAN; PENICILLIN RESISTANCE; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; BACILLUS; BRONCHI; BRONCHOSCOPY; EPITHELIUM; FOLIC ACID ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; MACROPHAGES, ALVEOLAR; MALE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; RESPIRATORY MUCOSA;

EID: 34548138988     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm242     Document Type: Article

References (10)

1. Sorbera LA, Castaner J, Rabasseda X. Iclaprim. Drugs Future 2004; 29: 220-5.
2. John BA, Henderson SJ, Harris SE et al. Metabolism and pharmacokinetics of iclaprim mesylate in humans. In: Posters of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Washington, DC, USA: American Society for Microbiology.
3. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996; 37 Suppl A: 57-63.
4. Andrews JM, Honeybourne D, Brenwald NP et al. Concentrations of Trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: 797-802.
5. The BAL Cooperative Group Steering Committee Bronchoalveolar lavage constituents in healthy individuals idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Resp Dis 1990; 141: 169-202.
6. Allen JG, Nimmo-Smith RH. Trimethoprim J. Reeves DS, Phillips I, Williams JD, Wise R eds. Laboratory Methods in Antimicrobial Chemotheraphy Edinburg Churchill Livingstone 1978; 227-31.
7. Bennet JV, Brodle JL, Benner EJ et al. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol 1996; 14: 170-7.
8. Hansen IB, Lykkegaard Nielsen M, Heerfordt L et al Trimethoprim in normal and pathological human lung tissue. Chemotherapy 1973; 19: 221-34.
9. Hansen IB, Lykkegaard Nielsen M, Bertelsen S. Trimethoprim in human saliva, bronchial secretion and lung tissue. Acta Pharmacol Toxicol 1973; 32: 337-44.
10. Andrews JM. BSAC standardized disc susceptibility testing method (version 3). J Antimicrob Chemother 2004; 53: 713-28.